CN102989064B - Sacculus medicine-spraying device for treating nasosinusitis or allergic rhinitis - Google Patents
Sacculus medicine-spraying device for treating nasosinusitis or allergic rhinitis Download PDFInfo
- Publication number
- CN102989064B CN102989064B CN201210454436.9A CN201210454436A CN102989064B CN 102989064 B CN102989064 B CN 102989064B CN 201210454436 A CN201210454436 A CN 201210454436A CN 102989064 B CN102989064 B CN 102989064B
- Authority
- CN
- China
- Prior art keywords
- sacculus
- spraying device
- medicine
- tube
- foley
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The invention provides a sacculus medicine-spraying device for treating nasosinusitis or allergic rhinitis. The sacculus medicine-spraying device comprises an inflatable sacculus, a sacculus inner pipe and a sacculus catheter, wherein the sacculus inner pipe penetrates through the sacculus and extends axially; and the far-end opening of the sacculus catheter is ended in the sacculus. The sacculus medicine-spraying device provided by the invention has the advantages that the prepared effective treating medicine liquid or gelatinous or powdery solid particles can be conveyed to the diseased part of the paranasal sinus, and the cavity part of the frontal sinus and/or the maxillary sinus is used as a medicine storage device, so that the diseased part can be treated by medicines in enough-long treatment period. The sacculus medicine-spraying device also has the advantages that effective medicines are uniformly sprayed to the diseased part by minimally invasive surgery; the medicines stored on the frontal sinus and the maxillary sinus can be conveyed to the diseased part continuously in time along with the swinging of the cilium of the nasal cavity and the flowing of mucus of the nasal cavity; and before the stored medicines are metabolized, the medicines can be directly and continuously fed to the diseased part, and the treating effect of common medicine feeding is greatly improved.
Description
Technical field
The present invention relates to medical instruments field, relate more specifically to a kind of sacculus chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis.
Background technology
Sinusitis and allergic rhinitis are otorhinolaryngology commonly encountered diseases and frequently-occurring disease, betide between 5 ~ 79 years old.Hygiene department's investigation shows: the sickness rate of current global allergic rhinitis is up to 10% to 14%, and sinusitis sickness rate accounts for 15% left and right of population, and the whole world has 600,000,000 people nearly enduring " harassing and wrecking " of rhinitis to the fullest extent, and is progressively ascendant trend.
Wherein 66% asthmatic patient is the victim of allergic rhinitis.According to expert introduction, allergic rhinitis is as correctly treated, and exceedes 1/3 patient and finally develops into asthma.
Nasal sinuses claims again paranasal sinuses, paranasal sinus, is the nasal cavity sclerotin chamber of multiple gassiness around, and they all communicate with nasal cavity with tubule.They are hidden on nasal cavity side, and as shown in Figure 1, maxillary sinus 9 is positioned at nasal cavity both sides, upper jaw bone above eye socket; Sinus frontalis 7 is in frontal bone; Sieve hole 8 is positioned at the both sides on nasal cavity top, is made up of many gassiness loculuses in screen casing; Sphenoid sinus (not shown) is talked endlessly in bone nasal cavity rear.
Epidermal mucosa cell in normal person's nasal cavity and nasal sinuses continues there is limpid liquid secretion out, have again the pulsation of rule rate via the cilium above mucosa cells, by these secretions from nasal sinuses, flow to cavum nasopharyngeum, throat via nasal cavity backward and swallow again esophagus and stomach.General adult approximately secretes the mucus of 1 liter every day, maintains the humidity of nasal cavity and nasal sinuses inside by these mucus, and dust and the foreign body in absorbed air simultaneously, to protect the health of respiratory tract.Once because the invasion of virus, antibacterial, or the stimulation of foreign body, cause limpid mucus secretion to become pus thick, or cilium is lost the pulsation that has rule rate, the sensation that the nasal mucus that capital generation pus is thick or nasal mucus flow backwards, and cause rhinitis or the swelling of nose film, all can make these tubule obturations.In the time that these tubules are inaccessible, will have influence on nasal cavity mucus and remain in a standstill in nasal sinuses, impact discharge.If not diagnosis and treatment early, will develop and become sinusitis, allergic rhinitis or other rhinitis.
In the time of nasal sinuses inflammation, can cause headache, nasal obstruction, rhinorrhea, temporary olfactory disorder, fear of cold, heating, inappetence, constipation, whole body discomfort etc.Compared with small children child can vomit, the symptom such as diarrhoea, cough.Pus nasal mucus stimulates throat can also cause throat discomfort, pharyngolaryngitis etc.
And allergic rhinitis, patient contacts or sucks after sensitinogen conventionally, the IgE(IgE in body) can cause that mastocyte discharges histamine, causes anaphylaxis.Allergen is the antigen that inducing specific IgE antibody also reacts with it.Their multi-sources are in animal, plant, insecticide, fungus or occupational material.Allergen is mainly divided into inhalant allergen and food allergen.Inhalant allergen is the main cause of allergic rhinitis.Patient's main manifestations of allergic rhinitis is that telangiectasis, permeability increase and glandular secretion increase and eosinophilic granulocyte infiltration etc.If above-mentioned disease is shown effect repeatedly, can cause that mucosal epithelium layer proliferative changes, and causes mucosa plumpness and Polypoid changes.Its symptom is similar to flu, is mainly the diseases such as rhinocnesmus, nasal obstruction, rhinorrhea, sneeze and stream clear water shape nasal mucus (runny nose), and intermittence is shown effect repeatedly, the pale edema of nasal mucosa when outbreak.Seriously also likely can develop into sinusitis, asthma or ear infection.
Application for Drug therapy at nose diseases, adopts collunarium or the spray mode to nasal cavity spraying medicine traditionally.Research shows, due to blocking of tissue, under traditional therapeutic modality, active drug can not reach diseased region smoothly, can only, by the diseased region of the sending to inhomogeneous medicinal liquid that is no more than 30%, greatly reduce medication effect.
At present existing nasal cavity flushing device, can be with normal saline or the medicine liquid washing that contains medicine nasal cavity, but of short duration drug effect almost only limits in concha nasalis position, can not arrive sinus frontalis and maxillary sinus hole body inside, can not be to inflammation nasal sinuses direct effect, and most nasal sinuses generation pathological changes can relate to nearly all hole body.In fact, even if medicinal liquid can enter hole body cavity inside, and for sinus frontalis opening the hole body in bottom, cleaning or spray after medicine completes, nearly all medicinal liquid all can be flowed out by Dou Kou, permanently effective treatment is carried out in the medicine storage of also having no chance therein.
Functional nasal endoscope Minimally Invasive Surgery has especially significantly therapeutic effect to acute sinusitis and chronic sinusitis.Can remove accurately pathological tissues and bone, nasal sinuses opening is expanded, recover the normal physiological function of nasal sinuses.Findings in endoscopic sinus surgery has traditional sinusitis incomparable invasive of performing the operation.But nasal endoscopic surgery is expensive, to treat not thoroughly, very easily recurrence, repeats to control expense and causes patient spirit financial burden weight.
The operative therapy for the treatment of of allergic rhinitis mainly contains the treatment of nerve block art, low-temperature plasma art, the operation of concha nasalis inferior mucosa, reduces the operation of parasympathetic nervous irritability, and other operative therapy, but above-mentioned recurrence after operation rate is high, and expense is high.
Exactly because and the prolonged and repeated medicine of most of cacorhinia can not act on diseased region for a long time constantly, the treatment of discontinuity brings disease repeatedly to show effect.If can pass through simple Minimally Invasive Surgery, can the effect of more effective performance Drug therapy for the long-term site-directed quantitative administration of diseased region.
Application number is that the patent of CN200620161536.2 discloses " a kind of balloon dilatation catheter for the treatment of rhinitis, sinusitis ", and wherein, air bag can reach the object that expands nasal meatus.Common inflammation does not occur in nasal meatus, but in nasal sinuses position.And clinical fact shows, be only to nasal meatus mechanical expansion, be temporary dredging respiration channel, alleviate disease discomfort, the effect suffering for want of medical supplies is very limited to the therapeutic effect of disease.
Application number is that the patent of CN200420085915.9 discloses a kind of " irrigation of maxillary sinus convergent divergent channel ", and this convergent divergent channel is made up of silica gel, is placed on maxillary sinus windowing or maxillary sinus nature Dou Kou, by syringe pipe to carrying out irrigation and disinfection in nasal sinuses.As be placed on maxillary sinus windowing, and wound and the complication of having taked repeatedly inferior nasal meatus puncture operation to bring sufferer although sinusitis recurrence has been avoided in this convergent divergent channel design, antral window operation is also a kind of trauma operation, has equally traumatic harm.The known antral window operation of those skilled in the art is called again maxillary sinus fistulation, has following common complication: 1, nasolacrimal canal injury, after causing performing the operation, Ipsilateral is shed tears for a long time incessantly.2, too to the rear because of fistulation position, the nose that has damaged greater palatine artery props up, or too to the front, has damaged superior labial artery nose and has propped up, and causes epistaxis.3, cause concha nasalis inferior and nasal wall adhesion because post operative treatment is improper.In addition, the convergent divergent channel of this patent is claimed also can be placed on maxillary sinus nature Dou Kou, but as previously mentioned, because sinusitis patient causes because of natural hole stenostomy, this convergent divergent channel therefore with front wing and empennage is actually and cannot be positioned over maxillary sinus nature Dou Kou place, thereby the convergent divergent channel that cannot provide by this patent is directly sprayed onto medicine on sinusitis patient's disease sites.
Application number is that the patent of CN200780017176.6 discloses a kind of nose tear drainage system implants for Drug therapy, by this implant by drug effect in expection position on.Due to stenosis of lacrimal punctum, before inserting this implant, need to insert dilator to expand in advance lacrimal point at lacrimal point, the implant that contains medicine could enter into smoothly reservation position and play a role.In other words, the implant providing by means of this patent, cannot directly be sprayed onto medicine on sinusitis patient's disease sites equally.
US Patent No. 7,645, in 272B2 " devices; systems and methods for treatingdisorders of the ear; nose and throat ", show that a class is used for the device of nasal irrigation or sinus cavities, can inject nasal sinuses by liquid conditions such as liquid normal saline or pastille liquid medicine whereby.Under normal circumstances, be limited to the restriction to pressure bearing of nasal sinuses and surrounding tissue thereof, the liquid that disperses spray prescription formula to spray into single shaft punching can not cover pathological changes completely, and can only play simple rinse effect to nasal sinuses, and the time stopping in nasal sinuses is quite short.
Therefore, need a kind of device, can medicine be directly sprayed to diseased region by Minimally Invasive Surgery, and medicine is played a role for a long time.Can play qualitative change effect to nasal cavity diseases such as Drug therapy sinusitis.
Summary of the invention
The object of this invention is to provide a kind of sacculus chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis, by Minimally Invasive Surgery mode, slow release treatment medicine is directly sprayed to nasal cavity diseased region, and slow releasing pharmaceutical is stored in to nasal cavity, realize longer continued treatment, thereby reduce the possibility of the palindromias such as sinusitis or allergic rhinitis, and reach the object of thorough healing by treatment.
In order to solve the problems of the technologies described above, technical scheme of the present invention is to provide a kind of sacculus chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis, this sacculus chemical spraying device comprises sacculus, sacculus inner tube and foley's tube that can be full, described sacculus inner tube runs through described sacculus and extends axially, the distal openings of described foley's tube ends in described sacculus, and described sacculus is the large sacculus in middle little two after full.
The distal openings of described sacculus inner tube ends at diseased region, sinus frontalis and/or maxillary sinus.
The proximal openings of described foley's tube is connected with ball inflation pressure pump.
The proximal openings of described sacculus inner tube is connected with vacuum draw equipment and/or drug storage.
This sacculus chemical spraying device also comprises the second sacculus and the second foley's tube, and the wall of described the second sacculus has at least one spray medicine aperture, and the distal openings of described the second foley's tube ends in described the second sacculus.
The proximal openings of described the second foley's tube is connected with the second ball inflation pressure pump and/or drug storage.
Described spray medicine aperture is distributed on the wall of described the second sacculus equably.
The aperture of described spray medicine aperture is 0.1mm-2mm.
Described the second sacculus is positioned at diseased region, sinus frontalis and/or maxillary sinus.
The sacculus chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis of the present invention, the effective medicine liquid preparing or gel or pulverulent solids particle can be delivered to Paranasal sinus diseases position, and using sinus frontalis and (or) maxillary sinus cavity part as medicament reservoir, make diseased region within the sufficiently long treatment phase, can obtain Drug therapy.With US Patent No. 7,645,272B2 thinks ratio, and sacculus chemical spraying device of the present invention, except spraying medicine for liquid state, is mainly used in solid-state or gel state granule spray medicine, can connect other sprayer units granule is delivered to diseased region, sinus frontalis and/or maxillary sinus.Compared with pure liquid state, solid-state or gel medicine can bond together with nasal sinuses, be not easy to run off in a short time, and solid granulates medicine is more suitable for long-time slow release.
Other benefits of this device are, first, can active drug be evenly sprayed on to diseased region by Minimally Invasive Surgery; Further, the medicine that is stored in sinus frontalis and maxillary sinus can be delivered to diseased region continually in time along with flowing of the swing of nasal cavity cilium and nasal cavity mucus, before store medication metabolism is complete, can continue, to the direct administration of diseased region, significantly to promote common drug treatment effect.
Brief description of the drawings
Fig. 1 is the schematic diagram of human body nasal sinuses at head position;
Fig. 2 is the schematic diagram of the sacculus chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis according to a preferred embodiment of the present invention;
Fig. 3 is the schematic diagram of the sacculus chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis according to a further advantageous embodiment of the invention;
Fig. 4 is the partial enlarged drawing of the sacculus chemical spraying device of Fig. 3.
Detailed description of the invention
Below in conjunction with accompanying drawing, provide preferred embodiment of the present invention, and be described in detail, enable to understand better function, the feature of the sacculus chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis of the present invention.
For convenience of description, the term " near-end " that hereinafter used refers to one end nearer apart from operator, and " far-end " refers to the one end away from operation technique person.
Embodiment 1
As shown in Figure 2, the sacculus chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis according to a preferred embodiment of the present invention comprises sacculus 1, sacculus inner tube 4 and foley's tube 5 that can be full.
Wherein, Fig. 2 shows the full state of this sacculus 1, and this sacculus 1 can be compliant balloon or half compliant balloon.Sacculus inner tube 4 runs through this sacculus 1 and extends axially, wherein, the straight-through diseased region of distal openings 41 of this sacculus inner tube 4, and proximal openings 42 is connected with luer joint or rib-loop interface or horn-like interface, thus be connected with small size vacuum pumping equipment and/or drug storage (not shown).The radial diameter of this sacculus inner tube 4 is depicted as 1mm in the present embodiment.Should be appreciated that, the radial diameter of this sacculus inner tube 4 can regulate as required, and preferably, between 0.5-5mm, more preferably 1-3mm, guides seal wire to insert and liquid turnover thereby facilitate.The distal openings 51 of foley's tube 5 ends at sacculus 1 inside, and proximal openings 52 is connected with luer joint equally, thereby is connected with ball inflation pressure pump.
By foley's tube 5, ball inflation pressure pump is sacculus 1 pressurising, makes sacculus 1 arrive suitable full state, thereby makes diseased region softened.Little in the middle of the sacculus 1 of this full state is depicted as, the sacculus that two is large.Compared with ZL200620161536.2 of the prior art and ZL 201020180943.4, sacculus 1 provided by the present invention can be fastened on nasal sinuses mouth in use, and Dou Kou tissue is carried out to excipient arrangement.Those skilled in the art is known, nasal meatus and nasal sinuses are not a concept, sacculus in ZL200620161536.2 can be placed in nasal meatus, but in the time that it acts on the nasal sinuses place of conventionally easy inflammation, the squeezing action that only depends on the pressure of the full expansion of sacculus to bring, can only push each nasal sinuses, impossible smooth opening Dou Kou, discharges luminal sectetion thing smoothly.Different from closed housings such as blood vessels, nasal sinuses opening is not the long tract that diameter seamlessly transits, and hole mouth length is quite short, and one section is opened on hole body inside, and the other end is opened in nasal meatus.It is stable that to open Dou Kou and make it to keep as far as possible the long enough time be the key that ensures successful surgery and therapeutic effect.How ZL 201020180943.4 does not provide and opens inaccessible Dou Kou with foley's tube, even closed Dou Kou can be opened by this invention foley's tube, after external force is removed (being after sacculus is removed), the Dou Kou opening still can be closed, is not enough to provide sufficiently long chronotherapy window.Sacculus 1 of the present invention is designed to the large middle small difference shape in full rear two, in the time that nasal sinuses port part is opened, can be applicable to well the shape of Dou Kou, after full by nasal sinuses mouth cartilage to extrapolation, and by hole mouth excipient, Dou Kou is maintained to unimpeded state more enduringly, make hole body recover nature physiological status.Thereby after hole mouth excipient, providing time enough window for thoroughly curing nasal cavity intractable pathological changes, this is thoroughly to treat pathological changes and the key of being avoided it repeatedly to show effect.By sacculus inner tube 4, seal wire can extend into diseased region and perform the operation, and in this operation process, the secretions of diseased region excretes under the effect of vacuum draw equipment by sacculus inner tube 4 equally.After this suction completes, by foley's tube 5, the pressure of sacculus 1 is by removal.By sacculus inner tube 4, the herbal sprinkling in drug storage, to diseased region, makes medicine paste invest diseased region surface.
In the present embodiment, the radical length of the mid portion of the sacculus 1 under full state is depicted as 5mm, and the radical length of two head part is preferably than the large 5mm of the radical length of mid portion.Should be appreciated that, the radical length of the mid portion of the sacculus 1 under full state can be adjusted as required, is preferably approximately 2 ~ 10mm, and the radical length of two head part also can be adjusted as required, preferably than the about 2 ~ 20mm of the radical length of mid portion.Clinical anatomic proves, the individual variation of nose and nasal sinuses is very large.Nose and nasal sinuses seem not yet to reach a stable Evolutionary Levels.The adaptation of morphological function is also being proceeded.In part, frequent visible anatomical variation has proved this viewpoint.The size of sacculus 1 is to determine according to the shape of nasal sinuses body, makes sacculus can be applicable to the size of nasal sinuses mouth and nasal sinuses inside, and therefore, for being applicable to different nasal sinuses shape and sizes, the size Selection of sacculus 1 is more wide in range.
With respect to traditional employing collunarium or spray, to the mode of nasal cavity spraying medicine (be only no more than 30% medicinal liquid sent to diseased region), the application, directly for the administration of diseased region site-directed quantitative, brings into play the therapeutical effect of medicine more effectively.
Alternatively, in use, the distal openings 41 of this sacculus inner tube 4 ends in the cavity of sinus frontalis 7 or maxillary sinus 9, medicine in drug storage is transported to by sacculus inner tube 4 in the cavity of sinus frontalis 7 or maxillary sinus 9, and now the re-entrant portion of this sinus frontalis 7 or maxillary sinus 9 is as the temporary memory of medicine.
Mode (most medicinal liquid flows out along spraying path) with respect to traditional employing collunarium or from spray to nasal cavity spraying medicine, the application is directly by the cavity of medicament storage and sinus frontalis or maxillary sinus, this medicine is along with swing and the flowing of nasal cavity mucus of nasal cavity cilium are delivered to diseased region continually in time, make diseased region can within the sufficiently long treatment phase, continue to obtain Drug therapy, significantly promote the effect of drug treatment.
Embodiment 2
As shown in Figure 3, the sacculus chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis according to a preferred embodiment of the present invention comprises the first sacculus 10, the second sacculus 20, the second foley's tube 30, sacculus inner tube 40 and first foley's tube 50 that can fill.
Wherein, Fig. 3 shows the full state of this sacculus 10, and this sacculus 10 can be compliant balloon or half compliant balloon.Sacculus inner tube 40 runs through the first sacculus 10 and the second sacculus 20 extends axially, wherein, the straight-through diseased region of distal openings 410 of this sacculus inner tube 40, and proximal openings 420 is connected with luer joint or rib-loop interface or horn-like interface, thus be connected with small size vacuum pumping equipment.The radial diameter of this sacculus inner tube 40 is depicted as about 3mm in the present embodiment.Should be appreciated that, the radial diameter of this sacculus inner tube 40 can regulate as required, and preferably, between 0.5-5mm, more preferably 1-3mm, guides seal wire to insert and liquid turnover thereby facilitate.
The distal openings 510 of the first foley's tube 50 ends at the first sacculus 10 inside, and proximal openings 520 is connected with luer joint, thereby is connected with ball inflation pressure pump.The distal openings 310 of the second foley's tube 30 ends at the second sacculus 20 inside, and proximal openings 320 is connected with luer joint, thereby is connected with drug storage and/or ball inflation pressure pump.
In the present embodiment, the radical length of the mid portion of the first sacculus 10 under full state is depicted as 10mm, and the radical length of two head part is preferably than the large 5mm of the radical length of mid portion.Should be appreciated that, the radical length of the mid portion of the sacculus 10 under full state can be adjusted as required, is preferably approximately 2 ~ 30mm, and the radical length of two head part is preferably than the about 2 ~ 30mm of the radical length of mid portion.
The partial enlarged drawing of the second sacculus 20 is shown in Figure 4, and the wall of the second sacculus 20 is uniform-distribution with spray medicine aperture 210, and quantity and the aperture of spray medicine aperture 210 determine according to the design of medicament categories, spray value demand and drug delivery balloon 20.For example, the quantity of this spray medicine aperture 210 is preferably at least one, is preferably more than 3.In the present embodiment, the aperture of this spray medicine aperture is depicted as 0.5mm.Should be appreciated that, the aperture of this spray medicine aperture can be adjusted as required, is preferably 0.1mm-2mm, more preferably 0.5mm-1mm.
The administering mode relating to according to two sacculus of the present embodiment is as follows: by the first foley's tube 50, ball inflation pressure pump is sacculus 10 pressurisings, makes sacculus 10 arrive suitable full state, thereby makes diseased region softened.By sacculus inner tube 40, seal wire can extend into diseased region and perform the operation, and in this operation process, the secretions of diseased region excretes under the effect of vacuum draw equipment.After this suction completes, by the first foley's tube 50, the pressure of sacculus 10 is by removal.By the second foley's tube 30, the drug conveying in drug storage is to the second sacculus 20, and medicine is sprayed onto diseased region by spray medicine aperture 210, makes medicine paste invest diseased region surface.
As from the foregoing, the suction of the secretions of diseased region realizes by sacculus inner tube 40, and the transfer passage of medicine is realized by the second foley's tube 30, thereby has effectively reduced the pollution of medicine.In addition, by the spray medicine aperture on the second sacculus 20, medicine can be sprayed to diseased region surface accurately, thereby realize the more medication of science.
Alternatively, this second sacculus 20 is positioned at sinus frontalis 7 or maxillary sinus 9, medicine in drug storage is transported to sinus frontalis 7 or maxillary sinus 9, and the re-entrant portion of this sinus frontalis 7 or maxillary sinus 9, as medicament reservoir, makes diseased region within the sufficiently long treatment phase, can obtain Drug therapy.
The related spendable medicine of sacculus chemical spraying device of the present invention can be liquid or solid-state.Liquid medicinal liquid is that solid active drug is added in carrying solvent under normal circumstances, make solution, emulsion or suspension, conventional solvent is the sodium chloride brine of mass percent concentration 0.3%-4.0%, and preferred concentration is 0.7%-0.9%, then active drug is dissolved in wherein, is mixed with medicinal liquid.Under this concentration, the pH of saline and environment in nasal cavity are nearest, and nose cilium optimum under this concentration and pH swings, and most of rhinitis pathological changes is all because the imbalance of nasal cavity mucus cilia motor function causes.
Solid-state medicine adopts the means such as grinding, atomization that medicine bulky grain solid is decomposed to micron or nano_scale particle, then medicine is delivered to affected part by device under gas pressure.In other implementations, drug microparticles may form suspension state, by pressure vessel, it is delivered to target location with liquid.In the outstanding mixed liquid of this class, drug microparticles should be distributed in liquid by uniformity, for reaching this purpose, should select suitable liquid, particle coagulation is dropped to minimum.Described pressure vessel divides inside and outside two-layer room, and with valve by Liang Shi UNICOM, after valve open, suspension can be by force feed to target location.
In other implementation, under normal room temperature and atmospheric pressure, suspension solvent is liquid condition in pressure vessel, after once pressurized is sprayed by pressure vessel, the suspension discharging under room temperature and atmospheric pressure is vaporized rapidly, thereby only there is drug microparticles to be taken to tissue surface, and there is no suspension solvent.This type of typical suspension solvent comprises hydrofluoroalkane based compound (HFA), for example HFA134 and HFA227ea.
Further, degradable controlled release polymer can be made equally to micron or nano-scale particle and together be sprayed into affected part, and then inject suitable solvent (as 0.7%-0.9% normal saline) to nasal cavity.Under the effect of body temperature and solvent, there is swelling swelling in degradable polymer microgranule, forms more stable slow releasing pharmaceutical coating with drug microparticles.
Above-described available medicine includes but are not limited to following listed medicine, long-acting steroids hormone, anti-inflammatory drug, anti-allergic drug, parasympatholytic, antihistaminic medicine, anti-infective, antiplatelet drug, anticoagulation, antithrombotic, anti-cicatrix medicine, antiproliferative pharmaceutical, chemotherapeutic, antineoplastic agent, the congested agent of solution, accelerator for concrescence, vitamin (as: tretinoin, vitamin A, vitamin B, and spin-off), immuno modulating agent, immunosuppressant, and the compositions of above-mentioned medicament or mixture.
Above-described slow release degradable polymer is polylactic acid and derivant thereof, copolymer, blend.Can regulate the molecular size range of slow release degradable polymer to regulate degradation rate, and then regulate slow release speed.Slow-release time is controlled at 1 day to 90 days, and preferred slow-release time is 3 to 30 days.
Closer, the polymer of mixing can be at least comprising 2 kinds of different microgranules, and every kind of microgranule is made up of variety classes polymer or variety classes combination of polymers respectively.Typically design is, wherein a kind of microgranule is made up of degradable polymer, and another kind of microgranule is made up of water-soluble polymer.Relative mass and the volume of relative mass in compositions of degradable polymer and water-soluble polymer or volume and the two microgranule are suitable.
Normally, make microgranule as far as possible fully cover contact and form firmly binding film at tissue surface, the microgranule in combination is quite little.Microgranule average particle size distribution should be at 50 nanometers to 500 micron support, or particle size distribution is narrower, between 700 nanometers to 200 micron.
This class degradable polymer and water-soluble polymer, and their compositions, wherein the composition of composition is very large on quality of forming film impact, also can affect after film forming bonding force and durability degree with tissue.In certain embodiments, the mass percent of degradable polymer or degradable polymer mixture can be 1-99,10-90,20-90,30-90,40-90,50-90,60-90,70-90,10-80,10-70,10-60,10-50,10-40,10-30,20-80,30-70, or 40-60.In certain embodiments, the mass percent of water-soluble polymer or water-soluble polymer mixture can be 10-90,20-90,30-90,40-90,50-90,60-90,70-90,10-80,10-70,10-60,10-50,10-40,10-30,20-80,30-70, or 40-60.
Degradable polymer comprises synthetic and the natural polymer that hydrolytic degradation can occur.Synthetic hydrolysis degradable polymer comprises and comprises that Poly(D,L-lactide-co-glycolide (poly (L-lactide-co-glycolide), PLGA) is at interior hydrolysis degradable polyester.Typical natural degradable polymer comprises chitin.Typical water-soluble polymer comprises Polyethylene Glycol (PEG), polyethyleneglycol block copolymer (for example PEG/PLGA taking Polyethylene Glycol unit as macromolecular chain tail end, PEG/PLA diblock or triblock copolymer, or PEG/PLGA, PEG/PLA diblock or three block random copolymerizations, alternate copolymer), sucrose, starch, Algin, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA).Polyvinyl alcohol (PVA) is a kind of typical easily hygroscopic polymer, and swelling and chemical degradation can occur under the state that has water.The above polymer, except sucrose, all has the feature of easy moisture absorption.
The performance of film forming caudacoria, particularly along with degraded deepens continuously, film can be adhered to maintaining the time of film forming brute force and time that film is etched completely and can be controlled by adjusting the ratio of lactide (LA) and Acetic acid, hydroxy-, bimol. cyclic ester (GA) in copolymer.In the time that the mol ratio of lactide (LA) has 100% decline gradually or rise gradually by 0%, the degree of crystallinity of copolymer is tending towards declining, and causes powerful decline.In addition, the external degradation time of known PLGA can reduce, in the time that the mol ratio of lactide (LA) has 100% decline gradually or rise gradually by 0%.
Above-described, be only preferred embodiment of the present invention, not in order to limit scope of the present invention, the above embodiment of the present invention can also make a variety of changes.Be that simple, the equivalence that every claims according to the present patent application and description are done changes and modify, all fall into the claim protection domain of patent of the present invention.The present invention not detailed description be routine techniques content.
Claims (8)
1. one kind is used for the treatment of the sacculus chemical spraying device of sinusitis or allergic rhinitis, this sacculus chemical spraying device comprises first sacculus (10) that can fill, sacculus inner tube (40) and the first foley's tube (50), described sacculus inner tube (40) runs through described the first sacculus (10) and extends axially, the distal openings (510) of described the first foley's tube (50) ends in described the first sacculus (10), it is characterized in that, described the first sacculus (10) is the large sacculus in middle little two after full, this sacculus chemical spraying device also comprises the second sacculus (20) and the second foley's tube (30), the wall of described the second sacculus (20) has at least one spray medicine aperture (210), the distal openings (310) of described the second foley's tube (30) ends in described the second sacculus (20), described sacculus inner tube (40) runs through described the second sacculus (20) and extends axially, by described the first foley's tube (50), to described the first sacculus (10), pressurising makes it arrive full state, thereby make diseased region softened, conduct drugs to described the second sacculus (20) by described the second foley's tube (30), medicine is sprayed onto diseased region by described spray medicine aperture (210).
2. sacculus chemical spraying device as claimed in claim 1, is characterized in that, the distal openings (410) of described sacculus inner tube (40) ends at diseased region.
3. sacculus chemical spraying device as claimed in claim 1, is characterized in that, the proximal openings (520) of described the first foley's tube (50) is connected with ball inflation pressure pump.
4. sacculus chemical spraying device as claimed in claim 1, is characterized in that, the proximal openings (420) of described sacculus inner tube (40) is connected with vacuum draw equipment.
5. sacculus chemical spraying device as claimed in claim 1, is characterized in that, the proximal openings (320) of described the second foley's tube (30) is connected with the second ball inflation pressure pump and/or drug storage.
6. sacculus chemical spraying device as claimed in claim 1, is characterized in that, described spray medicine aperture (210) is distributed on the wall of described the second sacculus (20) equably.
7. sacculus chemical spraying device as claimed in claim 1, is characterized in that, the aperture of described spray medicine aperture (210) is 0.1mm-2mm.
8. sacculus chemical spraying device as claimed in claim 1, is characterized in that, described the second sacculus (20) is positioned at diseased region, sinus frontalis and/or maxillary sinus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210454436.9A CN102989064B (en) | 2012-11-13 | 2012-11-13 | Sacculus medicine-spraying device for treating nasosinusitis or allergic rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210454436.9A CN102989064B (en) | 2012-11-13 | 2012-11-13 | Sacculus medicine-spraying device for treating nasosinusitis or allergic rhinitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102989064A CN102989064A (en) | 2013-03-27 |
| CN102989064B true CN102989064B (en) | 2014-08-06 |
Family
ID=47918488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210454436.9A Active CN102989064B (en) | 2012-11-13 | 2012-11-13 | Sacculus medicine-spraying device for treating nasosinusitis or allergic rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102989064B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104905957A (en) * | 2015-06-30 | 2015-09-16 | 福州创方医药科技有限公司 | Paranasal sinus expansion washing device and application method thereof |
| CN109758278B (en) * | 2019-01-27 | 2020-12-04 | 乐畅医疗器械(上海)有限公司 | Self-expansion nasal sinus support and taking and placing device thereof |
| CN112472981A (en) * | 2020-12-03 | 2021-03-12 | 李勋光 | Three-dimensional anesthesia ware of throat |
| CN114984420A (en) * | 2022-06-20 | 2022-09-02 | 柏为（武汉）医疗科技股份有限公司 | Sinus ostial stent expansion device and sinus ostial stent |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2772451Y (en) * | 2005-03-25 | 2006-04-19 | 无锡市第四人民医院 | Maxiliary sinus drainage inducing anti-adhesive device |
| WO2012030668A1 (en) * | 2010-08-30 | 2012-03-08 | SinuSys Corporation | Device and kit for inserting a sinus dilator |
| CN202314874U (en) * | 2011-11-27 | 2012-07-11 | 王保华 | Nasosinusitis therapy tube |
| CN102551836A (en) * | 2012-01-13 | 2012-07-11 | 西安交通大学 | Multifunctional shape-adaptability therapeutic device for nose |
| CN102600546A (en) * | 2011-03-01 | 2012-07-25 | 劳伦斯.J.格兰斯 | Nested balloon catheter for localized drug delivery |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7410480B2 (en) * | 2004-04-21 | 2008-08-12 | Acclarent, Inc. | Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders |
-
2012
- 2012-11-13 CN CN201210454436.9A patent/CN102989064B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2772451Y (en) * | 2005-03-25 | 2006-04-19 | 无锡市第四人民医院 | Maxiliary sinus drainage inducing anti-adhesive device |
| WO2012030668A1 (en) * | 2010-08-30 | 2012-03-08 | SinuSys Corporation | Device and kit for inserting a sinus dilator |
| CN102600546A (en) * | 2011-03-01 | 2012-07-25 | 劳伦斯.J.格兰斯 | Nested balloon catheter for localized drug delivery |
| CN202314874U (en) * | 2011-11-27 | 2012-07-11 | 王保华 | Nasosinusitis therapy tube |
| CN102551836A (en) * | 2012-01-13 | 2012-07-11 | 西安交通大学 | Multifunctional shape-adaptability therapeutic device for nose |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102989064A (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9381328B2 (en) | Balloon system for treating sinusitis or allergic rhinitis | |
| CN102988122B (en) | Prosthetic system for treating nasosinusitis or allergic rhinitis | |
| JP5763097B2 (en) | Apparatus and method for treating sinus disease | |
| US10869913B2 (en) | Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets | |
| Lam et al. | Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic | |
| CA2721985C (en) | Thiolated chitosan gel for treating mucosal tissue | |
| CN102989064B (en) | Sacculus medicine-spraying device for treating nasosinusitis or allergic rhinitis | |
| CN102988299B (en) | Formation method of drug coating and drug coating prepared by same | |
| US20220379101A1 (en) | Nasal Device for Treatment | |
| EP2632502A1 (en) | Artificial scab for use in an airway | |
| CN106137482A (en) | A kind of nasal sinuses support and induction system | |
| US20180236209A1 (en) | Method ofchronic urethral syndrome treatment | |
| CN102989065A (en) | Medicine spraying device for treating nasosinusitis or allergic rhinitis | |
| CN1379674B (en) | Ciclesonide contained pharmaceutical composition for application to mucosa | |
| Schilling et al. | Advances in controlled drug delivery to the sinonasal mucosa | |
| CN106139291A (en) | A kind of irrigation of sinuses conduit | |
| CN204951924U (en) | A slowly -releasing medicine support for nasal cavity | |
| CN204766774U (en) | Implantation system that nasal sinus washed pipe and washed pipe including this nasal sinus | |
| CN112292158A (en) | Foam formulations and methods of delivery to the body | |
| CN106344232A (en) | Sustained release medicine bracket for nasal cavity, forming method and application thereof | |
| US8211460B2 (en) | Formulations, devices and methods for treating and preventing mucositis | |
| CN204766053U (en) | Nasal sinus support and conveying system | |
| US20190070342A1 (en) | Free-standing biodegradable patch | |
| CN2636887Y (en) | Catheter for spray medicine feeder | |
| US20210330900A1 (en) | TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EoE) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 201203 room 218, innovation park of traditional Chinese medicine, No. 199, GuoShouJing Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Patentee after: Puyi (Shanghai) Biotechnology Co.,Ltd. Address before: 201203 room 218, innovation park of traditional Chinese medicine, No. 199, GuoShouJing Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Patentee before: PUYI (SHANGHAI) BIOTECHNOLOGY Co.,Ltd. |